Perawatan kanggo kanker paru-paru gumantung saka pirang-pirang faktor, kalebu tahap kanker, jinis kanker paru-paru, lan kesehatan umum pasien.
Sawetara pilihan perawatan sing umum kalebu:
1. Operasi: Iki asring dadi perawatan sing luwih disenengi kanggo kanker paru-paru tahap awal.
Ahli bedah mbusak tumor lan bagean cilik saka jaringan sing sehat ing saubengé.
2. Terapi radiasi: Radiasi energi dhuwur digunakake kanggo mateni sel kanker lan nyuda tumor.
Bisa digunakake piyambak utawa ing kombinasi karo perawatan liyane.
3. Kemoterapi: Perawatan iki migunakaké obat-obatan kanggo matèni sel kanker.
Bisa diwenehake kanthi intravena utawa lisan, lan asring digunakake bebarengan karo perawatan liyane.
4. Terapi sing ditargetake: Perawatan iki ngarahake gen utawa protein tartamtu sing nyumbang kanggo tuwuh lan kaslametan sel kanker.
Iki asring digunakake kanggo kanker paru-paru sing maju utawa metastatik.
5. Imunoterapi: Perawatan iki mbantu sistem kekebalan awak ngenali lan nyerang sel kanker.
Iki asring digunakake kanggo kanker paru-paru sing maju utawa metastatik.
6. Terapi fotodinamik: Perawatan iki nggunakake obat sing diaktifake cahya kanggo mateni sel kanker.
Iki asring digunakake kanggo kanker paru-paru tahap awal.
7. Terapi proton: Iki minangka jinis terapi radiasi sing nggunakake proton tinimbang sinar-X kanggo ngirim radiasi menyang tumor.
Iki asring digunakake kanggo kanker paru-paru tahap awal.
8. Uji coba klinis: Pasien bisa uga nduweni hak kanggo melu uji coba klinis kanggo nyoba perawatan anyar utawa kombinasi perawatan.
Penting kanggo ngrembug pilihan perawatan sing paling apik karo tim perawatan kesehatan, amarga rencana perawatan sing paling efektif bakal gumantung karo kahanan khusus individu kasebut.
Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.
Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.
Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.
Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.
Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.
Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.
Penafian: medis
Situs web iki diwenehake mung kanggo tujuan pendhidhikan lan informasi lan ora dadi menehi saran medis utawa layanan profesional.
Informasi sing diwenehake ora kudu digunakake kanggo diagnosa utawa ngobati masalah utawa penyakit kesehatan, lan wong-wong sing golek saran medis pribadi kudu takon karo dokter sing duwe lisensi.
Mangga dicathet jaringan saraf sing ngasilake wangsulan kanggo pitakonan, utamané ora akurat nalika nerangake konten numerik. Contone, jumlah wong sing didiagnosis karo penyakit tartamtu.
Tansah golek saran saka dhokter utawa panyedhiya kesehatan sing berkualitas liyane babagan kahanan medis. Aja ora nggatekake saran medis profesional utawa telat nggoleki amarga apa sing wis diwaca ing situs web iki. Yen sampeyan mikir sampeyan bisa duwe darurat medis, nelpon 911 utawa pindhah menyang kamar darurat paling cedhak langsung. Ora ana hubungan dokter-pasien sing digawe dening situs web iki utawa panggunaan. Ora BioMedLib utawa karyawan, utawa kontributor situs web iki, nggawe perwakilan, ekspres utawa tersirat, babagan informasi sing diwenehake ing kene utawa panggunaan.
Penafian: hak cipta
Undhang-undhang Hak Cipta Milenium Digital taun 1998, 17 U.S.C. § 512 ( DMCA) nyedhiyakake recourse kanggo pamilik hak cipta sing percaya yen materi sing katon ing Internet nglanggar hak-hak miturut hukum hak cipta AS.
Yen sampeyan percaya kanthi tulus manawa konten utawa materi sing kasedhiya gegayutan karo situs web utawa layanan kita nglanggar hak cipta sampeyan, sampeyan (utawa agen sampeyan) bisa ngirim kabar kanggo njaluk supaya konten utawa materi kasebut dicopot, utawa akses diblokir.
Kabar kudu dikirim kanthi nulis liwat email (deleng bagean "Kontak" kanggo alamat email).
DMCA mbutuhake kabar sampeyan babagan pelanggaran hak cipta sing diduga kalebu informasi ing ngisor iki: (1) deskripsi karya hak cipta sing dadi subyek pelanggaran sing diduga; (2) deskripsi konten sing diduga nglanggar lan informasi sing cukup kanggo ngidini kita nemokake konten kasebut; (3) informasi kontak kanggo sampeyan, kalebu alamat, nomer telpon lan alamat email; (4) pernyataan dening sampeyan yen sampeyan duwe kapercayan sing apik yen konten kanthi cara sing dikritik ora diidini dening pemilik hak cipta, utawa agen, utawa dening operasi hukum apa wae;
(5) pratelan dening sampeyan, ditandatangani kanthi paukuman sumpah palsu, manawa informasi ing pemberitahuan kasebut akurat lan sampeyan duwe wewenang kanggo ngetrapake hak cipta sing diklaim dilanggar;
lan (6) tandha tangan fisik utawa elektronik saka pemilik hak cipta utawa wong sing sah tumindak atas jenenge pemilik hak cipta.
Ora kalebu kabeh informasi ing ndhuwur bisa nyebabake wektu tundha kanggo ngolah keluhan sampeyan.
Kontak karo
Mangga ngirim kita email karo sembarang pitakonan / saran.
How to treat lung cancer?
The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.
Some common treatment options include:
1. Surgery: This is often the preferred treatment for early-stage lung cancer.
The surgeon removes the tumor and a small portion of healthy tissue around it.
2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.
It can be used alone or in combination with other treatments.
3. Chemotherapy: This treatment uses drugs to kill cancer cells.
It can be given intravenously or or orally, and is often used in combination with other treatments.
4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.
It is often used for advanced or metastatic lung cancer.
5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.
It is often used for advanced or metastatic lung cancer.
6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.
It is often used for early-stage lung cancer.
7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.
It is often used for early-stage lung cancer.
8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.
It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Kira-kira
BioMedLib nggunakake komputer otomatis (algoritma pembelajaran mesin) kanggo ngasilake pasangan pitakonan lan wangsulan.
Kita miwiti karo 35 yuta publikasi biomedis saka PubMed/Medline. Uga, kaca web saka RefinedWeb.
Deleng "Referensi" uga "Penolakan tanggung jawab".
